Skip to content
Screener

Albemarle ALB Other Reconciling Items To Adjusted EBITDA

Other Reconciling Items To Adjusted EBITDA at other companies

Fastenal logo
FastenalFAST
-$2.58M+74.3%
Corebridge Financial logo
Corebridge FinancialCRBG
$990M+1.6%
Corebridge Financial logo
Corebridge FinancialCRBG
$489M-9.6%
Corebridge Financial logo
Corebridge FinancialCRBG
$990M+1.6%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$0
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$0

Other financials

Income statement

See full
Revenue$1.7B+31.1%
Gross profit$590.3M+200%
Operating income$452.9M+853%
Net income$480.0M+1,996%
EPS (diluted)$3.52+2,300%

Balance sheet

See full
Cash & equivalents$1.6B-9.7%
Total debt$2.1B-45.5%
Total equity$10.3B+0.3%
Total assets$15.9B-8.0%

Cash flow

See full
Operating cash flow$710.0M
CapEx$71.7M-40.0%
Free cash flow$638.3M

Valuation

See full
Market cap$14.02B+77.0%
Enterprise value$14.49B+45.2%
P/E62.5×
P/S2.4×+0.8×

Profitability

See full
Gross margin23.8%+16.1pp
Operating margin4.3%+2.3pp
Net margin3.8%+2.1pp
FCF margin22.7%

Returns & leverage

See full
Return on equity2.2%+1.2pp
Debt / equity0.2×-0.2×
Current ratio2.1×-0.2×

Where this comes from

Reported directly by Albemarle in its filing.

Tagged under the XBRL concept alb:OtherReconcilingItemsToAdjustedEBITDA.

The source filing: Albemarle’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:40 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000915913-26-000102
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Proportionate share of Windfield income tax expense(b)(70,766)(33,150)(112,300)(58,476)
Loss on sale of business/equity investment, net(c)(52,718)
Acquisition and integration related costs(d)(765)(1,768)(1,872)(3,208)
Restructuring charges and asset write-offs(e)(7,337)(4,284)(33,203)(3,451)
Non-operating pension and OPEB items(854)(336)(2,201)(611)
Gain (loss) in fair value of public equity securities(f)6,5301861,043(4,836)
Other(g)(24,219)(21,462)(28,446)(9,275)
Net income attributable to Albemarle Corporation$479,959$22,897$799,050$64,245

Item 1. Financial Statements (Unaudited).

FAQ

What is Albemarle's other reconciling items to adjusted EBITDA?
Albemarle (ALB) reported other reconciling items to adjusted EBITDA of $24.22M in Q2 2026.
How has Albemarle's other reconciling items to adjusted EBITDA changed year-over-year?
Albemarle's other reconciling items to adjusted EBITDA increased by 12.8% year-over-year, from $21.46M to $24.22M.
What does other reconciling items to adjusted EBITDA mean?
Other Reconciling Items To Adjusted EBITDA as reported by Albemarle Corporation.

Ask your AI about Albemarle's other reconciling items to adjusted ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude